Liver Diseases Therapeutics Market by Products (Vaccines, Antiviral Drugs, Targeted Therapy, Immunosuppressants, Chemotherapy, Immunoglobulins, and Corticosteroids) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

The global liver diseases therapeutics market size is projected to register a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing incidences of hepatocellular carcinoma and other chronic diseases.

Liver disease is inherited or is caused by various elements that damage the liver due to excessive usage of alcohol or the virus infection. If the disease is not timely treated, it can damage the liver that further leads to liver failure. Thus, some of the key drugs are used in the diagnosis of several types of liver diseases that include immunosuppressants, vaccines, antiviral drugs, and chemotherapy drugs. The presence of vaccination campaigns introduced by the governments and key major companies are spreading awareness about the diseases and its preventions.

For instance, the China Government spent over USD 420 million to inoculate nearly 140 million unvaccinated children in 2011. In the U.S., the Affordable Care Act was focusing on the expansion of access to diagnosis, viral hepatitis prevention, and treatment and care.

The COVID-19 pandemic directly cause to rapid surge in liver infection cases. The reason of liver injury by the COVID?19 can be driven by various factors including hypoxia, virus?induced systemic inflammation, drug-induced liver disease, and hepatic congestion. In addition, the COVID?19 adversely affected outcomes of patients with chronic liver disease and accelerated the fatality rate of the COVID patients. Hence, there is a surge in the diagnosis, treatment, and follow-up of patients with liver disease, this has positively impacted the overall market revenue.  

Market Trends, Drivers, Restraints, and Opportunities

• Increasing prevalence of hepatocellular carcinoma and other liver diseases along with the presence of huge unmet needs of patients worldwide are expected to boost the market in the coming years.
• Growing number of geriatric population globally is expected to drive the market growth during the forecast period.
• Strong pipeline by biotechnology and pharmaceutical companies are the key elements expected to enhance liver diseases therapeutics. This is projected to fuel the market growth during the forecast period.
• Rising number of vaccination programs introduced by several healthcare bodies and governments’ initiatives for spreading awareness about the diseases and prevention are expected to propel the market during the forecast period.
• Extensive R&D investments by major pharmaceutical companies in order to develop the study insights and new approaches are expected to accelerate the market expansion.
• Risks and adverse reactions linked with present clinical treatments and controlled FDA and other government approval norms are key challenges expected to hamper the market growth.

Scope of the Liver Diseases Therapeutics Market Report                         

The report on the global liver diseases therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Liver Diseases Therapeutics Market Segment Insights

Antiviral drugs segment is expected to grow at a rapid pace

Based on products, the global liver diseases therapeutics market is divided into vaccines, antiviral drugs, targeted therapy, immunosuppressants, chemotherapy, immunoglobulins, and corticosteroids. The antiviral drugs segment accounted for a key share of the market in 2019 and is expected to grow at a rapid pace during the forecast period. The segment growth is attributed to increasing population with rising number of alcohol consumption, and increasing the prevalence of liver diseases. However, the chemotherapy segment is estimated to expand at a robust growth rate during the forecast period due to advancement in medical diagnosis in the field.

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to constitute a key market share in the coming years due to the wide engagement in academic and research institutes initiating medical trial studies in the region. The market of Asia Pacific, however, is expected to grow rapidly during the forecast period owing to supportive government initiatives in various countries of the region such as Japan and Australia. Moreover, favorable government policies pertaining to drug price adjustment and the development of novel drugs for the treatment of liver diseases in the region present key drivers of the market growth in Asia Pacific.

Segments

The global liver diseases therapeutics market has been segmented on the basis of

Products

• Vaccines
• Antiviral Drugs
• Targeted Therapy
• Immunosuppressants
• Chemotherapy
• Immunoglobulins
• Corticosteroids

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Astellas Pharma Inc.
• Abbott Laboratories
• Bristol-Mayers Squibb
• GlaxoSmithKline plc.
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche AG
• Novartis International AG
• Merck & Co., Inc.
• Sanofi S.A.
• Takeda Pharmaceuticals
• Pfizer Inc.
• Watson Pharmaceuticals
• Bausch Health Companies Inc.

Competitive Landscape

Key players competing in the global liver diseases therapeutics market are Astellas Pharma Inc.; Abbott Laboratories;  Bristol-Mayers Squibb; GlaxoSmithKline plc.; Gilead Sciences, Inc.; F. Hoffmann-La Roche AG; Novartis International AG; Merck & Co., Inc.; Sanofi S.A.; Takeda Pharmaceuticals; Pfizer Inc.; Watson Pharmaceuticals; and Bausch Health Companies Inc. The main market players are continuously engaged in market development activities such as mergers and acquisitions, research and developments, investments for innovative products and collaborations. For instance, GSK declared the US FDA approval of PROMACTA for the diagnosis of thrombocytopenia in patients in November 2012.